Group 1 - MIRXES-B has established a strategic partnership with N Health to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step in early cancer detection and improving patient outcomes in the region [1] - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1] - The partnership aims to leverage the increasing awareness of preventive healthcare and the rising prevalence of chronic diseases to create an ideal environment for adopting innovative diagnostic technologies like miRNA testing [1] Group 2 - The company launched a new series of home screening test kits in Thailand, including HELICORapid for detecting H. pylori infections and FITRapid for detecting fecal occult blood, both of which are significant cancer risk factors [2] - These home testing kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into a streamlined component, reducing processing steps and minimizing contamination risks [2] - The company aims to expand its sales and marketing efforts into the consumer sector, providing easy-to-use and hygienic home testing options while maintaining scientific rigor and user safety [2]
MIRXES-B(02629.HK)：已在泰国推出新系列的居家筛查检测试剂盒